| Literature DB >> 32527230 |
Zara Steinmeyer1, Cyrille Delpierre2, Gaelle Soriano3, Armand Steinmeyer3, Loic Ysebaert4, Laurent Balardy3, Sandrine Sourdet3.
Abstract
BACKGROUND: Frailty and hemoglobin concentration, above what would be considered clinical anemia, are two common findings in older patients that lead to an increased risk of negative health outcomes. The objective of this study is to evaluate whether hemoglobin concentration is an independent predictor of frailty and investigate possible causal pathways with a focus on the relationship between inflammation or nutrition and hemoglobin concentration.Entities:
Keywords: Frailty-hemoglobin-Anemia
Mesh:
Substances:
Year: 2020 PMID: 32527230 PMCID: PMC7291509 DOI: 10.1186/s12877-020-01597-6
Source DB: PubMed Journal: BMC Geriatr ISSN: 1471-2318 Impact factor: 3.921
Fig. 1Flow chart showing sample selection
Baseline characteristics of the study subjects
| Baseline Characteristic ( | ||
|---|---|---|
| Available data | Included ( | |
| Age, mean (SD), years | 1905 | 82.44 (6.50) |
| Gender, Male, n(%) | 1905 | 597 (32.64) |
| School education, n(%) | ||
| Low level of education | 1811 | 677 (37.01) |
| Middle level of education | 711 (38.87) | |
| High level of education | 357 (19.52) | |
| Living arrangements n(%) | ||
| Living alone | 1874 | 842 (46.04) |
| Living with others | 959 (52.43) | |
| Hypertension n(%) | 1814 | 952 (52.05) |
| Diabetes mellitus n(%) | 1814 | 261 (14.27) |
| Atrial arrhythmia n(%) | 1811 | 278 (15.20) |
| Thrombo embolic disease n(%) | 1808 | 141 (7.71) |
| Cardiovascular disease n(%) | 1810 | 269 (14.71) |
| Congestive heart failure n(%) | 1813 | 103 (5.63) |
| Chronic respiratory disease n(%) | 1269 | 17 (0.93) |
| Renal insufficiency n(%) | 1269 | 57 (3.12) |
| Connectivitis n(%) | 1814 | 62 (3.39) |
| Prebaseline cancer n(%) | 1814 | 337 (18.43) |
| Frailty Fried’s criteria | ||
| Non frail | 1886 | 936 (51.18) |
| Frail | 893 (48.82) | |
| Cognitive: MMSE score (%) | ||
| No impairment ≥26 | 1851 | 961 (52.54) |
| Mild impairment 21–25 | 484 (26.46) | |
| Moderate impairment 11–20 | 310 (16.95) | |
| Severe impairment 0–10 | 27 (1.48) | |
| Nutritional status | ||
| MNA score ≥ 24 | 1847 | 1084 (59.27) |
| MNA score 17–23.5 | 610 (33.35) | |
| MNA score < 17 | 81 (4.43) | |
| ADL score(/6), median (IQR) | 1899 | 6 (1) |
| IADL score(/8), median (IQR) | 1884 | 6 (4) |
| Hemoglobin, Mean ± SD g/dl | 1854 | 13.33 (1.41) |
| Mean corpuscular volume, median (IQR), fl | 1854 | 91 (6) |
| White blood cell count, median (IQR), 10^3/cm | 1854 | 6.63 (2.38) |
| Platelets, median (IQR), 10^3/cm | 1832 | 231 (80) |
| Anemia n(%) | 1832 | 381 (20.83) |
| C-reactive protein, median (IQR), mg/L | 1861 | 2.1 (3.9) |
| Renal function: CKD-EPI MD | ||
| Normal (eGFR ≥90 ml/min/1.73m2), n(%) | 1875 | 162 (8.86) |
| Mild decrease (eGFR 60–89 ml/min/1.73m2), n(%) | 1120 (61.24) | |
| Moderate to severe decrease (eGFR 30–59 ml/min/1.73m2), n(%) | 484 (26.46) | |
| Severe decrease (eGFR≤29 ml/min/1.73m2), n(%) | 43 (2.35) | |
SD Standard deviation, IQR Inter quartile; MMSE: Mini mental state examination, MNA Mini nutritional assessment, ADL Activities of daily living, IADL Instrumental activities of daily living
Cardiovascular disease: Arrythmia, coronary artery disease, pulmonary hypertension, heart valve problems, congestive heart failure, hypertension, cholesterol, obliterating artery disease, thrombosis, pulmonary embolism;Cancer: leukemia, lymphoma, multiple myeloma, solid cancer
CKD-EPI MD: Chronic kidney disease epidemiology collaboration; eGFR: Equations for glomerular filtration rate
Odds of being Frail. Multivariate regression models (N = 1599)
| Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR | CI 95% | p | OR | CI 95% | p | OR | CI 95% | p | OR | CI 95% | P | OR | CI 95% | p | OR | CI95% | p | |
| < 79 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||
| 79–83 | 1.49 | (1.11–2.00) | 0.008* | 1.53 | (1.14–2.06) | 0.005* | 1.58 | (1.17–2.14) | 0.003* | 1.52 | (1.12–2.06) | 0.007* | 1.58 | (1.15–2.18) | 0.005* | 1.56 | (1.13–2.14) | 0.007* |
| 83–87 | 1.99 | (1.48–2.65) | < 0.001* | 2.03 | (1.50–2.75) | < 0.001* | 2.10 | (1.55–2.85) | < 0.001* | 1.84 | (1.35–2.52) | < 0.001* | 1.84 | (1.33–2.55) | < 0.001* | 1.86 | (1.34–2.57) | < 0.001* |
| > 87 | 3.80 | (2.80–5.12) | < 0.001* | 3.85 | (2.80–5.28) | < 0.001* | 4.03 | (2.92–5.56) | 0.000* | 3.45 | (2.49–4.79) | 0.000* | 3.20 | (2.27–4.49) | < 0.001* | 3.23 | (2.29–4.55) | < 0.001* |
| Male | 1 | 1 | 1 | 1 | 1 | 1 | ||||||||||||
| Female | 1.41 | (1.12–1.77) | 0.004* | 1.42 | (1.13–1.79) | 0.003* | 1.48 | (1.17–1.88) | 0.001* | 1.48 | (1.16–1.88) | 0.001* | 1.44 | (1.13–1.85) | 0.004* | 1.48 | (1.14–1.92) | 0.003* |
| 0.78 | (0.72–0.85) | < 0.001* | 0.79 | (0.73–0.86) | < 0.001* | 0.81 | (0.75–0.89) | < 0.001* | 0.82 | (0.75–0.89) | < 0.001* | 0.86 | (0.79–0.94) | 0.001* | 0.86 | (0.79–0.94) | 0.001* | |
| Normal | 1 | 1 | 1 | 1 | 1 | |||||||||||||
| Mild decrease | 0.75 | (0.51–1.10) | 0.14 | 0.75 | (0.51–1.11) | 0.15 | 0.77 | (0.52–1.15) | 0.20 | 0.80 | (0.53–1.21) | 0.30 | 0.82 | (0.54–1.25) | 0.36 | |||
| Moderate to severe decrease | 0.82 | (0.53–1.25) | 0.36 | 0.81 | (0.52–1.24) | 0.33 | 0.84 | (0.54–1.30) | 0.43 | 0.88 | (0.56–1.40) | 0.60 | 0.90 | (0.57–1.44) | 0.67 | |||
| Severe decrease | 0.92 | (0.40–2.08) | 0.84 | 0.82 | (0.36–1.87) | 0.64 | 0.86 | (0.37–1.99) | 0.72 | 0.84 | (0.35–2.00) | 0.70 | 0.80 | (0.34–1.91) | 0.62 | |||
| No inflammation | 1 | 1 | 1 | 1 | ||||||||||||||
| Inflammation | 2.25 | (1.58–3.20) | < 0.001* | 2.26 | (1.58–3.25) | < 0.001* | 2.11 | (1.45–3.07) | < 0.001* | 2.12 | (1.45–3.09) | < 0.001* | ||||||
| No impairment | 1 | 1 | 1 | |||||||||||||||
| Mild impairment | 1.74 | (1.36–2.22) | < 0.001* | 1.53 | (1.18–1.98) | 0.001* | 1.44 | (1.10–1.87) | 0.007* | |||||||||
| Moderate impairment | 2.27 | (1.68–3.08) | < 0.001* | 1 .81 | (1.32–2.50) | < 0.001* | 1.65 | (1.18–2.31) | 0.003* | |||||||||
| Severe impairment | 4.29 | (1.60–11.51) | 0.004* | 1.98 | (0.71–5.51) | 0.19 | 1.72 | (0.62–4.81) | 0.30 | |||||||||
| Normal | 1 | 1 | ||||||||||||||||
| Risk of malnutrition | 3.23 | (2.53–4.11) | 0.000* | 3.24 | (2.55–4.13) | < 0.001* | ||||||||||||
| Malnutrition | 8.21 | (4.03–16.74) | 0.000* | 8.15 | (4.00–16.60) | < 0.001* | ||||||||||||
| Low level of education | 1 | |||||||||||||||||
| Middle level of education | 0.91 | (0.70–1.18) | 0.47 | |||||||||||||||
| High level of education | 0.69 | (0.50–0.95) | 0.025* | |||||||||||||||
| Living alone | 1 | |||||||||||||||||
| Living with others | 0.80 | (0.63–1.01) | 0.06 | |||||||||||||||
eGFR Equations for glomerular filtration rate, CRP C-reactive protein, MMSE Mini mental state examination, MNA Mini nutritional assessment
* P<0.05